Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Chowers

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Virology|December 1, 1994
Cell surface CD4 downregulation and resistance to superinfection induced by a defective provirus of HIV-1S J Little, N L Riggs, M Y Chowers, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2015
Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawalS Ben-Horin, Y Chowers, B Ungar, et al.
Gut|October 4, 2008
Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurinesS Ben-Horin, I Goldstein, E Fudim, et al.
Emerging Infectious Diseases|December 2, 2005
Long-term Death Rates, West Nile virus epidemic, Israel, 2000Manfred S Green, Miriam Weinberger, Judith Ben-Ezer, et al.
Alimentary Pharmacology & Therapeutics|November 11, 2017
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapyH Bar-Yoseph, N Levhar, L Selinger, et al.
Gastroenterology|September 30, 1998
Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study GroupS Bar-Meir, Y Chowers, A Lavy, et al.
Cellular Immunology|May 12, 2009
The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's diseaseA Ochaion, S Bar-Yehuda, S Cohen, et al.
Alimentary Pharmacology & Therapeutics|February 1, 2012
The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBDS Ben-Horin, Y Mazor, H Yanai, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2016
Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumabB Ungar, U Kopylov, T Engel, et al.
Clinical and Experimental Immunology|April 8, 2015
Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trialE Israeli, E Goldin, S Fishman, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Virology|December 1, 1994
Cell surface CD4 downregulation and resistance to superinfection induced by a defective provirus of HIV-1S J Little, N L Riggs, M Y Chowers, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2015
Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawalS Ben-Horin, Y Chowers, B Ungar, et al.
Gut|October 4, 2008
Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurinesS Ben-Horin, I Goldstein, E Fudim, et al.
Emerging Infectious Diseases|December 2, 2005
Long-term Death Rates, West Nile virus epidemic, Israel, 2000Manfred S Green, Miriam Weinberger, Judith Ben-Ezer, et al.
Alimentary Pharmacology & Therapeutics|November 11, 2017
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapyH Bar-Yoseph, N Levhar, L Selinger, et al.
Gastroenterology|September 30, 1998
Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study GroupS Bar-Meir, Y Chowers, A Lavy, et al.
Cellular Immunology|May 12, 2009
The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's diseaseA Ochaion, S Bar-Yehuda, S Cohen, et al.
Alimentary Pharmacology & Therapeutics|February 1, 2012
The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBDS Ben-Horin, Y Mazor, H Yanai, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2016
Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumabB Ungar, U Kopylov, T Engel, et al.
Clinical and Experimental Immunology|April 8, 2015
Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trialE Israeli, E Goldin, S Fishman, et al.
Pageof 6